Biolevate has closed a 30 million euro Series A and opened an office in Boston, which puts the French company built by former Dataiku engineers within reach of the pharma customers it is chasing.
Co-leading the round are Orange Ventures and RAISE France, a pair that also brought along the MSD Global Health Innovation Fund, Station F, and returning backer EQT Ventures.
The platform takes on the paperwork that stalls drug programs, spanning literature reviews, evidence synthesis, regulatory submissions and health technology assessments. Scientific and regulatory knowledge goes in and auditable workflows come out, with a person signing off on every result and a link back to the evidence it rests on.
The company says a single run can put 100,000 agents to work, that literature reviews finish 16 times sooner, and that regulatory intelligence comes out 80% more efficient. More than 12 enterprise customers run it in production, and annual recurring revenue grew 20-fold in a year. Biolevate lists Sanofi, NVIDIA and Microsoft as partners, and has prepared seven patent applications, two of which went to Europe.
Headcount reached 50 and should double next year. Aymar Henin becomes chairman, while Jerome Berger, who runs group strategy and venture capital at Orange, takes a board seat. EQT wrote the 6 million euro seed check in November 2024, back when the startup was still a medical-writing play.
Why it matters. Regulated industries adopt AI slowly, because an output nobody can audit is worthless inside a filing. Biolevate is betting that traceability, not fluency, is what pharmaceutical companies will pay for.
